November 25, 2019 / 10:35 AM / 14 days ago

BRIEF-PTC Therapeutics Announces FDA Grants Priority Review To Risdiplam For The Treatment Of Spinal Muscular Atrophy

Nov 25 (Reuters) - PTC Therapeutics Inc:

* PTC THERAPEUTICS ANNOUNCES FDA GRANTS PRIORITY REVIEW TO RISDIPLAM FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY

* PTC THERAPEUTICS INC - PDUFA DATE SET FOR MAY 24, 2020

* PTC THERAPEUTICS INC - FILING ACCEPTANCE BY FDA TRIGGERS $15 MILLION MILESTONE PAYABLE TO PTC BY ROCHE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below